Federated Hermes Inc. Sells 365,642 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Federated Hermes Inc. lessened its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 15.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,045,958 shares of the company's stock after selling 365,642 shares during the quarter. Federated Hermes Inc. owned approximately 3.57% of Structure Therapeutics worth $55,486,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd raised its stake in shares of Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after acquiring an additional 553 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after purchasing an additional 1,122 shares during the period. FNY Investment Advisers LLC acquired a new stake in shares of Structure Therapeutics in the fourth quarter worth $40,000. Assetmark Inc. boosted its holdings in shares of Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after buying an additional 953 shares during the period. Finally, Headlands Technologies LLC bought a new stake in shares of Structure Therapeutics during the 4th quarter worth $113,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GPCR has been the topic of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. William Blair began coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating for the company. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $50.00 price target on the stock. Finally, JMP Securities reissued a "market outperform" rating and issued a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $81.29.

Remove Ads

Structure Therapeutics Trading Up 5.6 %

NASDAQ GPCR traded up $0.85 during trading hours on Friday, reaching $15.90. 510,397 shares of the company's stock were exchanged, compared to its average volume of 870,798. The firm has a fifty day moving average of $20.98 and a 200-day moving average of $29.11. Structure Therapeutics Inc. has a one year low of $13.22 and a one year high of $62.74. The stock has a market cap of $911.75 million, a PE ratio of -21.49 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. As a group, research analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.